Allogene (ALLO) SVP/General Counsel Douglas Martin Sells 29,697 Shares

What Happened

• Douglas Earl Martin, SVP and General Counsel of Allogene Therapeutics (ALLO), sold 29,697 shares on 2026-08-21 at $2.12 per share, generating about $62,958. The sale was a "sell-to-cover" to satisfy tax withholding obligations tied to vesting restricted stock units and was not a discretionary open-market trade.

Key Details

• Transaction date and price: August 21, 2026 — 29,697 shares at $2.12 each (total ≈ $62,958).
• Transaction type: Sale (S) executed to cover tax withholding (see footnote F1).
• Shares owned after transaction: Not stated in the filing.
• Notable footnotes:
  • F1: Sale mandated by issuer's "sell to cover" election for tax withholding (not a discretionary trade).
  • F2: Reporting person had 54,479 performance RSUs forfeited (granted Aug 14, 2023).
  • F3: Filing notes inclusion of 7,495 shares acquired Mar 15, 2026 via the employee stock purchase program.
• Filing date and timeliness: Form 4 filed 2026-08-25 for an 2026-08-21 transaction; filing appears to be within the standard two-business-day reporting window.

Context

• Sell-to-cover transactions are routine administrative sales to satisfy tax obligations when RSUs vest and typically do not by themselves signal insider confidence or concern. The filing also shows a forfeiture of performance RSUs and prior ESPP purchases, which affect total potential and reported holdings but do not indicate new discretionary buying.